MCC950

Catalog No.S8930 Batch:S893002

Print

Technical Data

Formula

C20H24N2O5S
Molecular Weight 404.48 CAS No. 210826-40-7
Solubility (25°C)* In vitro DMSO 81 mg/mL (200.25 mM)
Ethanol 7 mg/mL (17.3 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 2.500mg/ml (6.18mM) Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
Targets
NLRP3 [1]
(BMDM-based assay)		 NLRP3 [1]
(HMDM-based assay)
7.5 nM 8.1 nM
In vitro

MCC950 specifically inhibits NLPR3 inflammasome activation.
In vivo

Inhibition of NLRP3 with MCC950 ameliorates proteinuria, renal histological lesions and podocyte foot process effacement in lupus-prone mice.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    NZM2328 podocyte cell line

  • Concentrations

    1 µM

  • Incubation Time

    24 h

  • Method

    The NZM2328 podocyte cell line was stimulated with a control serum or a serum from diseased NZM2328 mice or serum from diseased NZM2328 mice depleted of IgG, with or without MCC950 or Mito TEMPO for 24 hours. After this incubation, cells were subjected to flow cytometry and Western blot analyses for NLRP3 inflammasome activation, mitochondrial membrane potential and production of reactive oxygen species (ROS) analysis.

    (Data sourced from selleck products)
Animal Study:

[1]
  • Animal Models

    female NZM2328, a new NZM strain produced by extended backcrosses of NZB/WF1 to NZW mice

  • Dosages

    10mg/kg

  • Administration

    i.p.

    (Data sourced from selleck products)

References

  • https://pubmed.ncbi.nlm.nih.gov/28544564/
  • https://pubmed.ncbi.nlm.nih.gov/35294888/
  • https://pubmed.ncbi.nlm.nih.gov/36087465/

Selleck's MCC950 Has Been Cited by 150 Publications

Electroacupuncture Inhibits NLRP3-Mediated Microglial Pyroptosis to Ameliorate Chronic Neuropathic Pain in Rats [ Journal of Pain Research, March 7, 2025, 1115–1129] PubMed: 40070891
A new mechanism regulating microglial NLRP3 inflammasome: FMR1 mediates NLRP3 mRNA stability [ PLoS One, February 20, 2026, e0341867] PubMed: 41719238
NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy [ Cancer Immunology Research, December 2, 2022, 1542-1558] PubMed: 36255412
Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk [ Signal Transduct Target Ther, 2025, 10(1):157] PubMed: 40360476
Human heart-macrophage assembloids mimic immune-cardiac interactions and enable arrhythmia disease modeling [ Cell Stem Cell, 2025, 32(11):1671-1690.e13] PubMed: 41151577
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action [ J Exp Med, 2025, 222(11)e20242403] PubMed: 40892070
The inflammasome sensor NLRP3 interacts with REV7 to maintain genome integrity through homologous recombination [ Nucleic Acids Res, 2025, 53(12)gkaf554] PubMed: 40613708
PM2.5 exacerbates nasal epithelial barrier dysfunction in allergic rhinitis by inducing NLRP3-mediated pyroptosis via the AhR/CYP1A1/ROS axis [ J Hazard Mater, 2025, 492:138145] PubMed: 40209413
Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity [ J Immunother Cancer, 2025, 13(10)e012182] PubMed: 41052880
Monocyte membrane-coated drug nanocrystals for enhanced targeted therapy of rheumatoid arthritis [ J Control Release, 2025, 384:113919] PubMed: 40460929

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.